AbbVie Inc has acquired a Belgian neurology company for up to $1 billion in order to enrich its portfolio with assets designed to treat cognitive impairment. The company, Syndesi Therapeutics SA, was founded in 2017 through a partnership between UCB Pharma and Novo Seeds and supported by a syndicate of Belgian and international investors.
